Status:
COMPLETED
Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Lead Sponsor:
Royal Brisbane and Women's Hospital
Collaborating Sponsors:
The University of Queensland
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Ceftolozane/tazobactam is an emerging newly available antibiotic that has a broad spectrum of activity, and could be potentially useful in the management of central nervous system infections. However,...
Detailed Description
Although relatively less frequent, Gram negative nosocomial meningitis and ventriculitis are observed in critical care settings, often associated with brain trauma, brain surgery, spinal fluid shunt a...
Eligibility Criteria
Inclusion
- Patients with any infection requiring treatment with ceftolozane/tazobactam and who have met the following criteria:
- Age \>18 years
- The presence of an indwelling external ventricular drain (EVD) or requiring EVD insertion due to obstructive hydrocephalus/subarachnoid haemorrhage
Exclusion
- Known or suspected allergy to penicillins and cephalosporins
- Pregnancy
- Receiving renal replacement therapy
- Glomerular filtration rate less than 10 mL/min
- Receiving piperacillin/tazobactam or having received piperacillin/tazobactam in the past 7 days before enrolment
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03309657
Start Date
February 1 2018
End Date
June 1 2020
Last Update
September 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia, 4029